A New Era for Psychedelic Medicine | SALT Talks #143

Sa'ad Shah is the co-founder and managing partner of Noetic, a venture capital firm that seeks to invest in emerging and early-stage psychedelic-based wellness, therapeutic and pharmaceutical companies. JR Rahn is the co-founder and co-CEO of MindMed, a leading psychedelic medicine biotech company that discovers, develops and deploys psychedelic-inspired medicines and therapies to address addiction and mental illness. Psychedelics in medicine represent an entirely new biotech asset class. Psychedelics still carry with it the stigma of its recreational use in the 60s and 70s, but its application as therapy is intended to help people with mental health and addiction issues. Psychedelic-assisted therapy involves a trained therapist who guides the patient through the experience. "The science has been incredibly compelling. The efficacy rates cannot be ignored." ————————————————————————— To learn more about this episode, including podcast transcripts and show notes, visit salt.org/talks Moderated by Anthony Scaramucci.